UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
SCHEDULE 13D
(Rule 13d-101)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO
RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a)
(Amendment No. 1)*
Boston Biomedica, Inc.
---------------------------------------------------------------------------
(Name of Issuer)
Common Stock, $.01 par value per share
---------------------------------------------------------------------------
(Title of Class of Securities)
100560 10 1
---------------------------------------------------------------------------
(CUSIP Number)
Nutter, McClennen & Fish, LLP
World Trade Center West
155 Seaport Boulevard
Boston, MA 02210-2604
Attn: Michael J. Bohnen, Esq.
617-439-2000
---------------------------------------------------------------------------
(Name, Address and Telephone Number of Person Authorized
to Receive Notices and Communications)
March 25, 2003
---------------------------------------------------------------------------
(Date of Event Which Requires Filing of This Statement)
If the filing person has previously filed a statement on Schedule 13G to
report the acquisition which is the subject of this Schedule 13D, and is
filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check
the following box [___].
Note: Schedules filed in paper format shall include a signed original and
five copies of the schedule, including all exhibits. See Rule 13d-1(a) for
other parties to whom copies are to be sent.
(Continued on following pages)
(Page 1 of 6 Pages)
_____________________
* The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject
class of securities, and for any subsequent amendment containing
information which would alter disclosures provided in a prior cover
page.
The information required on the remainder of this cover page shall not be
deemed to be "filed" for the purpose of Section 18 of the Securities
Exchange Act of 1934 or otherwise subject to the liabilities of that
section of the Act but shall be subject to all other provisions of the Act
(however, see the Notes).
CUSIP No. 100560 10 1 SCHEDULE 13D Page 2 of 6 Pages
---------------------------------------------------------------------------
NAME OF REPORTING PERSONS
1 I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
R. Wayne Fritzsche
---------------------------------------------------------------------------
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
2 (a) [X]
(b) [_]
---------------------------------------------------------------------------
SEC USE ONLY
3
---------------------------------------------------------------------------
SOURCE OF FUNDS
4
00 (see Item 3)
---------------------------------------------------------------------------
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
5 PURSUANT TO ITEM 2(d) or 2(e) [_]
---------------------------------------------------------------------------
CITIZENSHIP OR PLACE OF ORGANIZATION
6
U.S.A.
---------------------------------------------------------------------------
NUMBER OF SOLE VOTING POWER
7
SHARES 3,000
-----------------------------------------------------
SHARED VOTING POWER
BENEFICIALLY 8
- 0 -
OWNED BY -----------------------------------------------------
SOLE DISPOSITIVE POWER
EACH 9
3,000
REPORTING -----------------------------------------------------
SHARED DISPOSITIVE POWER
PERSON 10
- 0 -
WITH
---------------------------------------------------------------------------
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
11
3,000
---------------------------------------------------------------------------
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
12 [_]
---------------------------------------------------------------------------
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
13
0.0%
---------------------------------------------------------------------------
TYPE OF REPORTING PERSON
14
IN
---------------------------------------------------------------------------
CUSIP No. 100560 10 1 SCHEDULE 13D Page 3 of 6 Pages
---------------------------------------------------------------------------
NAME OF REPORTING PERSONS
1 I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Russell B. Richerson, Ph.D.
---------------------------------------------------------------------------
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
2 (a) [X]
(b) [_]
---------------------------------------------------------------------------
SEC USE ONLY
3
---------------------------------------------------------------------------
SOURCE OF FUNDS
4
00 (see Item 3)
---------------------------------------------------------------------------
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
5 PURSUANT TO ITEM 2(d) or 2(e) [_]
---------------------------------------------------------------------------
CITIZENSHIP OR PLACE OF ORGANIZATION
6
U.S.A.
---------------------------------------------------------------------------
NUMBER OF SOLE VOTING POWER
7
SHARES 3,000
-----------------------------------------------------
SHARED VOTING POWER
BENEFICIALLY 8
2,000
OWNED BY -----------------------------------------------------
SOLE DISPOSITIVE POWER
EACH 9
3,000
REPORTING -----------------------------------------------------
SHARED DISPOSITIVE POWER
PERSON 10
2,000
WITH
---------------------------------------------------------------------------
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
11
5,000
---------------------------------------------------------------------------
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
12 [_]
---------------------------------------------------------------------------
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
13
0.0%
---------------------------------------------------------------------------
TYPE OF REPORTING PERSON
14
IN
CUSIP No. 100560 10 1 SCHEDULE 13D Page 4 of 6 Pages
---------------------------------------------------------------------------
NAME OF REPORTING PERSONS
1 I.R.S. IDENTIFICATION NOS. OF ABOVE PERSON (ENTITIES ONLY)
Richard T. Schumacher
---------------------------------------------------------------------------
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
2 (a) [X]
(b) [_]
---------------------------------------------------------------------------
SEC USE ONLY
3
---------------------------------------------------------------------------
SOURCE OF FUNDS
4
00 (see Item 3)
---------------------------------------------------------------------------
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
5 PURSUANT TO ITEM 2(d) or 2(e) [_]
---------------------------------------------------------------------------
CITIZENSHIP OR PLACE OF ORGANIZATION
6
U.S.A.
---------------------------------------------------------------------------
NUMBER OF SOLE VOTING POWER
7
SHARES 672,907
-----------------------------------------------------
SHARED VOTING POWER
BENEFICIALLY 8
- 0 -
OWNED BY -----------------------------------------------------
SOLE DISPOSITIVE POWER
EACH 9
672,907
REPORTING -----------------------------------------------------
SHARED DISPOSITIVE POWER
PERSON 10
- 0 -
WITH
---------------------------------------------------------------------------
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
11
672,907
---------------------------------------------------------------------------
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
12 [_]
---------------------------------------------------------------------------
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
13
9.9%
---------------------------------------------------------------------------
TYPE OF REPORTING PERSON
14
IN
---------------------------------------------------------------------------
Item 3. Source and Amount of Funds or Other Consideration.
Mr. Fritzsche acquired all of the Common Stock reported by him in
Item 5 below as consideration for service on the Scientific Advisory Board
of the Issuer.
Dr. Richerson purchased 2,000 shares of the Common Stock reported by
him in Item 5 below in two separate open market purchases of 1,000 shares
each on or about November 9, 2000 and December 1, 2000 and used an
aggregate of $5,410 of personal funds for such purchases. Dr. Richerson
acquired the remainder of the Common Stock reported by him in Item 5 below
as consideration for service on the Scientific Advisory Board of the
Issuer.
Mr. Schumacher acquired 597,907 shares of the Common Stock reported
by him in Item 5 below in connection with the founding of the Issuer and
used an aggregate of approximately $2,500 of personal funds for such
acquisition. Mr. Schumacher purchased an additional 75,000 shares of the
Common Stock reported by him in Item 5 below pursuant to the exercise of
stock options and used an aggregate of approximately $122,500 of personal
funds for such purchase. This amendment is being filed to reflect the
expiration of options to purchase 45,000 shares and the vesting of options
to purchase 10,000 shares for a net decrease of 35,000 shares.
Item 5. Interest in Securities of the Issuer.
(a) The aggregate number and percentage of Common Stock to which
this Statement relates is 680,907 shares, representing 9.9% of the shares
of Common Stock outstanding. The Reporting Persons beneficially own such
Common Stock as follows:
Name Shares of Common Stock % of Class
---- ---------------------- ----------
R. Wayne Fritzsche (1) 3,000 0.0%
Russell B. Richerson, Ph.D. (2) 5,000 0.0%
Richard T. Schumacher (3) 672,907 9.9%
TOTAL 680,907 9.9%
(1) Includes 3,000 shares issuable pursuant to options that currently are
exercisable.
(2) Includes 3,000 shares issuable pursuant to options that currently are
exercisable.
(3) Includes 35,000 shares issuable pursuant to options that currently
are exercisable or will be exercisable by June 15, 2003. This
amendment is being filed to reflect the expiration of options to
purchase 45,000 shares and the vesting of options to purchase 10,000
shares for a net decrease of 35,000 shares.
(b) Each of the Reporting Persons has the sole power to vote or
direct the vote and sole power to dispose or direct the disposition of the
Common Stock reported for such person, except that Dr. Richerson shares
voting and dispositive power with respect to 2,000 shares that are held by
the Richerson Living Trust dated 9/22/00, of which Dr. Richerson is a co-
trustee with his wife, with whom he shares voting and investment power over
these shares.
(c) During the past 60 days or since the most recent filing on
Schedule 13D, whichever is less, none of the Reporting Persons has effected
any transactions in the Common Stock.
(d) Not applicable.
(e) Not applicable.
5
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief,
I certify that the information set forth in this statement is true,
complete, and correct.
Date: April 16, 2003 R. Wayne Fritzsche
Russell B. Richerson, Ph.D.
Richard T. Schumacher
By: /s/ Richard T. Schumacher
--------------------------------
Richard T. Schumacher
Attorney-in-Fact
6